Sentence examples for rationale for evaluation from inspiring English sources

Although polymorphisms were not directly evaluated by Innocenti and colleagues, their clinical report suggested flavopiridol∶metabolite ratio as a possible predictor of diarrhea with flavopiridol treatment and provided a rationale for evaluation of a genetic link with UGT isoforms [31].

These studies provided the rationale for evaluation of bortezomib as a modifier of cell-cell adhesion and cellular packing density in solid tumours.

Our results thus provide a rationale for evaluation of combination therapy with ALK and MEK inhibitors in EML4 ALK-positive NSCLC patiEML4 ALK-positive iNSCLCtors alone show little effect.

These data provide the preclinical rationale for clinical evaluation of GRN163L in myeloma and in combination with 17AAG.

The results provide a strong rationale for clinical evaluation of dual BET/JAK inhibition in MPNs.

GRN163L is the first telomerase inhibitor validated for clinical study, and these data provide preclinical rationale for clinical evaluation of GRN163L in myeloma.

These preclinical data showing that GRN163L is a potent and specific telomerase inhibitor, provide the rationale for clinical evaluation of GNR163L in patients with relapsed multiple myeloma.

Our results also provide a rationale for clinical evaluation of the combinations of bortezomib and oridonin (or other inhibitors of NF-κB1/2) or AD 198 (or other drugs targeting c-Myc) in the treatment of lymphoma and MM, especially in patients containing TRAF3 deletions or relevant mutations.

Fellow volcanologist Wes Hildreth said of Johnston, "I think Dave's dearest hope was that systematic monitoring of fumarolic emissions might permit detection of changes characteristically precursory to eruptions ... Dave wanted to formulate a general model for the behavior of magmatic volatiles prior to explosive outbursts and to develop a corollary rationale for the evaluation of hazards".

PI3K-pathway upregulation in primary and metastatic prostate cancers provides the rationale for clinical evaluation of PI3K-pathway inhibitors (including rapalogs).

Our results provide a strong rationale for wider evaluation of serum miRNAs as biomarkers for management of oral malignancy.